SET and lung cancer: SET nuclear proto-oncogene (I2PP2A) is another potent endogenous PP2A inhibitor that is considered an oncogene in leukemia (AML, CLL & CML), lymphoma, CRC, breast, and lung cancer [9,10,18,79,80,81].